Ananda Pharma reports Phase 1 pharmacokinetic study results for MRX1

NMD Pharma reports further data from Phase 2a study of ignaseclant

Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat

Bayer completes acquisition of Perfuse Therapeutics to strengthen ophthalmology pipeline

Akeso reports Phase II data for ligufalimab in AML

Optimi Health introduces standardised microdose psilocybin capsules for clinical research

Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment

AlzeCure reports positive Phase Ib results for Alzheimer's candidate ACD856

Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026

Kalohexis presents dual MC3R/MC4R activation data at ENDO 2026

Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease

Lonza and Antharis Therapeutics enter target-specific licence agreement

Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes

Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment

Sensei Biotherapeutics changes name to Faeth Therapeutics